Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Katharina Hopp

TitleAssociate Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-1858
Email

    Collapse Biography 
    Collapse education and training
    Mayo Clinic, Rochester MNPhD12/2012Biochemistry & Molecular Biology
    Collapse awards and honors
    2018Dr. Vincent H. Gattone Research Award, PKD Foundation

    Collapse Overview 
    Collapse overview
    Dr. Hopp attempts to understand, through her research, the underlying pathomechanisms driving autosomal dominant polycystic kidney disease (ADPKD) progression. Specifically, she investigates genetic mechanisms driving phenotypic heterogeneity amongst patients by studying different murine models and by sequencing human samples. She also studies the renal cystic microenvironment to better understand the role of immune cells in ADPKD pathogenesis. Through this research, Dr. Hopp aims to identify novel pathways that can be translated into either pre-clinical or clinical trials geared to alleviate disease burden.

    Collapse Research 
    Collapse research activities and funding
    K01DK114164     (HOPP, KATHARINA)Aug 1, 2018 - Jul 31, 2023
    NIH
    Defining the functional role of T-cells in Autosomal Dominant Polycystic Kidney Disease pathology
    Role: Principal Investigator
    PKD Research Grant     (Katharina Hopp)Jul 1, 2018 - Jun 30, 2020
    PKD Foundation
    Understanding the role of CD8+ T-cells in halting renal cystogenesis
    Role: PI
    W81XWH-17-1-0107     (Katharina Hopp)Sep 1, 2017 - Mar 31, 2019
    DOD
    Application of the Sleeping Beauty transposon system to identify regulatory genes driving ADPKD cystogenesis and phenotypic heterogeneity
    Role: PI

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Kleczko EK, Nguyen DT, Marsh KH, Bauer CD, Li AS, Monaghan MT, Berger MD, Furgeson SB, Gitomer BY, Chonchol MB, Clambey ET, Zimmerman KA, Nemenoff RA, Hopp K. Immune checkpoint activity regulates polycystic kidney disease progression. JCI Insight. 2023 06 22; 8(12). PMID: 37345660.
      View in: PubMed
    2. Yashchenko A, Bland SJ, Song CJ, Ahmed UKB, Sharp R, Darby IG, Cordova AM, Smith ME, Lever JM, Li Z, Aloria EJ, Khan S, Maryam B, Liu S, Crowley MR, Jones KL, Zenewicz LA, George JF, Mrug M, Crossman DK, Hopp K, Stavrakis S, Humphrey MB, Ginhoux F, Zimmerman KA. Cx3cr1 controls kidney resident macrophage heterogeneity. Front Immunol. 2023; 14:1082078. PMID: 37256130.
      View in: PubMed
    3. Nguyen DT, Kleczko EK, Dwivedi N, Monaghan MT, Gitomer BY, Chonchol MB, Clambey ET, Nemenoff RA, Klawitter J, Hopp K. The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression. JCI Insight. 2023 01 10; 8(1). PMID: 36422996.
      View in: PubMed
    4. Kleczko EK, Poczobutt JM, Navarro AC, Laskowski J, Johnson AM, Korpela SP, Gurule NJ, Heasley LE, Hopp K, Weiser-Evans MCM, Gottlin EB, Bushey RT, Campa MJ, Patz EF, Thurman JM, Nemenoff RA. Upregulation of complement proteins in lung cancer cells mediates tumor progression. Front Oncol. 2022; 12:1045690. PMID: 36686777.
      View in: PubMed
    5. Klawitter J, Jackson MJ, Smith PH, Hopp K, Chonchol M, Gitomer BY, Cadnapaphornchai MA, Christians U, Klawitter J. Kynurenines in polycystic kidney disease. J Nephrol. 2023 01; 36(1):83-91. PMID: 35867237.
      View in: PubMed
    6. Meena P, Hopp K. The Enigma of Clinical Heterogeneity Among Autosomal Recessive Polycystic Kidney Disease Siblings: PKHD1 Genotype Versus Other Genomic or Environmental Modifier. Kidney Int Rep. 2022 Jul; 7(7):1453-1455. PMID: 35812282.
      View in: PubMed
    7. Klawitter J, Sempio C, Jackson MJ, Smith PH, Hopp K, Chonchol M, Gitomer BY, Christians U, Klawitter J. Endocannabinoid System in Polycystic Kidney Disease. Am J Nephrol. 2022; 53(4):264-272. PMID: 35263737.
      View in: PubMed
    8. Song CJ, Li Z, Ahmed UKB, Bland SJ, Yashchenko A, Liu S, Aloria EJ, Lever JM, Gonzalez NM, Bickel MA, Giles CB, Georgescu C, Wren JD, Lang ML, Benveniste EN, Harrington LE, Tsiokas L, George JF, Jones KL, Crossman DK, Agarwal A, Mrug M, Yoder BK, Hopp K, Zimmerman KA. A Comprehensive Immune Cell Atlas of Cystic Kidney Disease Reveals the Involvement of Adaptive Immune Cells in Injury-Mediated Cyst Progression in Mice. J Am Soc Nephrol. 2022 04; 33(4):747-768. PMID: 35110364.
      View in: PubMed
    9. Hopp K, Kleczko EK, Gitomer BY, Chonchol M, Klawitter J, Christians U, Klawitter J. Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease. Am J Physiol Renal Physiol. 2022 03 01; 322(3):F258-F267. PMID: 35037466.
      View in: PubMed
    10. Hopp K, Catenacci VA, Dwivedi N, Kline TL, Wang W, You Z, Nguyen DT, Bing K, Poudyal B, Johnson GC, Jackman MR, Miller M, Steele CN, Serkova NJ, MacLean PS, Nemenoff RA, Gitomer B, Chonchol M, Nowak KL. Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease. iScience. 2022 Jan 21; 25(1):103697. PMID: 35059607.
      View in: PubMed
    11. Montford JR, Bauer C, Rahkola J, Reisz JA, Floyd D, Hopp K, Soranno DE, Klawitter J, Weiser-Evans MCM, Nemenoff R, Faubel S, Furgeson SB. 15-Lipoxygenase worsens renal fibrosis, inflammation, and metabolism in a murine model of ureteral obstruction. Am J Physiol Renal Physiol. 2022 01 01; 322(1):F105-F119. PMID: 34866403.
      View in: PubMed
    12. Johnson AM, Boland JM, Wrobel J, Klezcko EK, Weiser-Evans M, Hopp K, Heasley L, Clambey ET, Jordan K, Nemenoff RA, Schenk EL. Cancer Cell-Specific Major Histocompatibility Complex II Expression as a Determinant of the Immune Infiltrate Organization and Function in the NSCLC Tumor Microenvironment. J Thorac Oncol. 2021 10; 16(10):1694-1704. PMID: 34048945.
      View in: PubMed
    13. Baliga MM, Klawitter J, Christians U, Hopp K, Chonchol M, Gitomer BY, Cadnapaphornchai MA, Klawitter J. Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease. Sci Rep. 2021 03 23; 11(1):6629. PMID: 33758231.
      View in: PubMed
    14. Arroyo J, Escobar-Zarate D, Wells HH, Constans MM, Thao K, Smith JM, Sieben CJ, Martell MR, Kline TL, Irazabal MV, Torres VE, Hopp K, Harris PC. The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1RC/RC mouse model of autosomal dominant polycystic kidney disease. Kidney Int. 2021 06; 99(6):1392-1407. PMID: 33705824.
      View in: PubMed
    15. Atwood DJ, Brown CN, Holditch SJ, Pokhrel D, Thorburn A, Hopp K, Edelstein CL. The effect of trehalose on autophagy-related proteins and cyst growth in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease. Cell Signal. 2020 11; 75:109760. PMID: 32866627.
      View in: PubMed
    16. Atwood DJ, Pokhrel D, Brown CN, Holditch SJ, Bachu DM, Thorburn A, Hopp K, Edelstein CL. Increased mTOR and suppressed autophagic flux in the heart of a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease. Cell Signal. 2020 10; 74:109730. PMID: 32730856.
      View in: PubMed
    17. Zimmerman KA, Hopp K, Mrug M. Role of chemokines, innate and adaptive immunity. Cell Signal. 2020 09; 73:109647. PMID: 32325183.
      View in: PubMed
    18. Johnson AM, Bullock BL, Neuwelt AJ, Poczobutt JM, Kaspar RE, Li HY, Kwak JW, Hopp K, Weiser-Evans MCM, Heasley LE, Schenk EL, Clambey ET, Nemenoff RA. Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma. J Immunol. 2020 04 15; 204(8):2295-2307. PMID: 32179637.
      View in: PubMed
    19. Nowak KL, Hopp K. Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential. Clin J Am Soc Nephrol. 2020 04 07; 15(4):577-584. PMID: 32086281.
      View in: PubMed
    20. Holditch SJ, Brown CN, Atwood DJ, Pokhrel D, Brown SE, Lombardi AM, Nguyen KN, Hill RC, Lanaspa M, Hopp K, Weiser-Evans MCM, Edelstein CL. The consequences of increased 4E-BP1 in polycystic kidney disease. Hum Mol Genet. 2019 12 15; 28(24):4132-4147. PMID: 31646342.
      View in: PubMed
    21. Nemenoff RA, Kleczko EK, Hopp K. Renal double negative T cells: unconventional cells in search of a function. Ann Transl Med. 2019 Dec; 7(Suppl 8):S342. PMID: 32016060.
      View in: PubMed
    22. Hopp K, Cornec-Le Gall E, Senum SR, Te Paske IBAW, Raj S, Lavu S, Baheti S, Edwards ME, Madsen CD, Heyer CM, Ong ACM, Bae KT, Fatica R, Steinman TI, Chapman AB, Gitomer B, Perrone RD, Rahbari-Oskoui FF, Torres VE, Harris PC. Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney Int. 2020 02; 97(2):370-382. PMID: 31874800.
      View in: PubMed
    23. Gewin LS, Summers ME, Harral JW, Gaskill CF, Khodo SN, Neelisetty S, Sullivan TM, Hopp K, Reese JJ, Klemm DJ, Kon V, Ess KC, Shi W, Majka SM. Inactivation of Tsc2 in Abcg2 lineage-derived cells drives the appearance of polycystic lesions and fibrosis in the adult kidney. Am J Physiol Renal Physiol. 2019 11 01; 317(5):F1201-F1210. PMID: 31461347.
      View in: PubMed
    24. Olson RJ, Hopp K, Wells H, Smith JM, Furtado J, Constans MM, Escobar DL, Geurts AM, Torres VE, Harris PC. Synergistic Genetic Interactions between Pkhd1 and Pkd1 Result in an ARPKD-Like Phenotype in Murine Models. J Am Soc Nephrol. 2019 11; 30(11):2113-2127. PMID: 31427367.
      View in: PubMed
    25. Bullock BL, Kimball AK, Poczobutt JM, Neuwelt AJ, Li HY, Johnson AM, Kwak JW, Kleczko EK, Kaspar RE, Wagner EK, Hopp K, Schenk EL, Weiser-Evans MC, Clambey ET, Nemenoff RA. Tumor-intrinsic response to IFN? shapes the tumor microenvironment and anti-PD-1 response in NSCLC. Life Sci Alliance. 2019 06; 2(3). PMID: 31133614.
      View in: PubMed
    26. Holditch SJ, Brown CN, Atwood DJ, Lombardi AM, Nguyen KN, Toll HW, Hopp K, Edelstein CL. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol. 2019 07 01; 317(1):F187-F196. PMID: 31042058.
      View in: PubMed
    27. Montford JR, Bauer C, Dobrinskikh E, Hopp K, Levi M, Weiser-Evans M, Nemenoff R, Furgeson SB. Inhibition of 5-lipoxygenase decreases renal fibrosis and progression of chronic kidney disease. Am J Physiol Renal Physiol. 2019 04 01; 316(4):F732-F742. PMID: 30649890.
      View in: PubMed
    28. Kleczko EK, Marsh KH, Tyler LC, Furgeson SB, Bullock BL, Altmann CJ, Miyazaki M, Gitomer BY, Harris PC, Weiser-Evans MCM, Chonchol MB, Clambey ET, Nemenoff RA, Hopp K. CD8+ T cells modulate autosomal dominant polycystic kidney disease progression. Kidney Int. 2018 12; 94(6):1127-1140. PMID: 30249452.
      View in: PubMed
    29. Boczek NJ, Hopp K, Benoit L, Kraft D, Cousin MA, Blackburn PR, Madsen CD, Oliver GR, Nair AA, Na J, Bianchi DW, Beek G, Harris PC, Pichurin P, Klee EW. Characterization of three ciliopathy pedigrees expands the phenotype associated with biallelic C2CD3 variants. Eur J Hum Genet. 2018 12; 26(12):1797-1809. PMID: 30097616.
      View in: PubMed
    30. Cornec-Le Gall E, Olson RJ, Besse W, Heyer CM, Gainullin VG, Smith JM, Audr?zet MP, Hopp K, Porath B, Shi B, Baheti S, Senum SR, Arroyo J, Madsen CD, F?rec C, Joly D, Jouret F, Fikri-Benbrahim O, Charasse C, Coulibaly JM, Yu AS, Khalili K, Pei Y, Somlo S, Le Meur Y, Torres VE, Harris PC. Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. Am J Hum Genet. 2018 05 03; 102(5):832-844. PMID: 29706351.
      View in: PubMed
    31. Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Ba?ales JM, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Vigneau C, Lavainne F, Audr?zet MP, Ferec C, Le Meur Y, Torres VE, Harris PC. Mutations in GANAB, Encoding the Glucosidase IIa Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. Am J Hum Genet. 2016 06 02; 98(6):1193-1207. PMID: 27259053.
      View in: PubMed
    32. Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, Hopp K, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016 09; 27(9):2872-84. PMID: 26823553.
      View in: PubMed
    33. Warner G, Hein KZ, Nin V, Edwards M, Chini CC, Hopp K, Harris PC, Torres VE, Chini EN. Food Restriction Ameliorates the Development of Polycystic Kidney Disease. J Am Soc Nephrol. 2016 05; 27(5):1437-47. PMID: 26538633.
      View in: PubMed
    34. Ye H, Wang X, Sussman CR, Hopp K, Irazabal MV, Bakeberg JL, LaRiviere WB, Manganiello VC, Vorhees CV, Zhao H, Harris PC, van Deursen J, Ward CJ, Torres VE. Modulation of Polycystic Kidney Disease Severity by Phosphodiesterase 1 and 3 Subfamilies. J Am Soc Nephrol. 2016 05; 27(5):1312-20. PMID: 26374610.
      View in: PubMed
    35. Kline TL, Irazabal MV, Ebrahimi B, Hopp K, Udoji KN, Warner JD, Korfiatis P, Mishra PK, Macura SI, Venkatesh SK, Lerman LO, Harris PC, Torres VE, King BF, Erickson BJ. Utilizing magnetization transfer imaging to investigate tissue remodeling in a murine model of autosomal dominant polycystic kidney disease. Magn Reson Med. 2016 Apr; 75(4):1466-73. PMID: 25974140.
      View in: PubMed
    36. Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC. Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria. J Am Soc Nephrol. 2015 Oct; 26(10):2559-70. PMID: 25644115.
      View in: PubMed
    37. Gainullin VG, Hopp K, Ward CJ, Hommerding CJ, Harris PC. Polycystin-1 maturation requires polycystin-2 in a dose-dependent manner. J Clin Invest. 2015 Feb; 125(2):607-20. PMID: 25574838.
      View in: PubMed
    38. Hopp K, Wang X, Ye H, Irazabal MV, Harris PC, Torres VE. Effects of hydration in rats and mice with polycystic kidney disease. Am J Physiol Renal Physiol. 2015 Feb 01; 308(3):F261-6. PMID: 25503729.
      View in: PubMed
    39. Hopp K. Improving HNF1? mutation detection rates: can a weighted score of clinical and familial characteristics help? Kidney Int. 2014 Nov; 86(5):882-4. PMID: 25360493.
      View in: PubMed
    40. Hopp K, Hommerding CJ, Wang X, Ye H, Harris PC, Torres VE. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J Am Soc Nephrol. 2015 Jan; 26(1):39-47. PMID: 24994926.
      View in: PubMed
    41. Paul BM, Consugar MB, Ryan Lee M, Sundsbak JL, Heyer CM, Rossetti S, Kubly VJ, Hopp K, Torres VE, Coto E, Clementi M, Bogdanova N, de Almeida E, Bichet DG, Harris PC. Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families. Kidney Int. 2014 Feb; 85(2):383-92. PMID: 23760289.
      View in: PubMed
    42. Harris PC, Hopp K. The mutation, a key determinant of phenotype in ADPKD. J Am Soc Nephrol. 2013 May; 24(6):868-70. PMID: 23687354.
      View in: PubMed
    43. Hopp K, Ward CJ, Hommerding CJ, Nasr SH, Tuan HF, Gainullin VG, Rossetti S, Torres VE, Harris PC. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest. 2012 Nov; 122(11):4257-73. PMID: 23064367.
      View in: PubMed
    44. Rossetti S, Hopp K, Sikkink RA, Sundsbak JL, Lee YK, Kubly V, Eckloff BW, Ward CJ, Winearls CG, Torres VE, Harris PC. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol. 2012 May; 23(5):915-33. PMID: 22383692.
      View in: PubMed
    45. Hopp K, Heyer CM, Hommerding CJ, Henke SA, Sundsbak JL, Patel S, Patel P, Consugar MB, Czarnecki PG, Gliem TJ, Torres VE, Rossetti S, Harris PC. B9D1 is revealed as a novel Meckel syndrome (MKS) gene by targeted exon-enriched next-generation sequencing and deletion analysis. Hum Mol Genet. 2011 Jul 01; 20(13):2524-34. PMID: 21493627.
      View in: PubMed
    46. Vujic M, Heyer CM, Ars E, Hopp K, Markoff A, Orndal C, Rudenhed B, Nasr SH, Torres VE, Torra R, Bogdanova N, Harris PC. Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD. J Am Soc Nephrol. 2010 Jul; 21(7):1097-102. PMID: 20558538.
      View in: PubMed
    47. Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley SW, Chauveau D, Rees L, Barratt TM, van't Hoff WG, Niaudet P, Niaudet WP, Torres VE, Harris PC. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int. 2009 Apr; 75(8):848-55. PMID: 19165178.
      View in: PubMed
    48. Ito O, Alonso-Galicia M, Hopp KA, Roman RJ. Localization of cytochrome P-450 4A isoforms along the rat nephron. Am J Physiol. 1998 02; 274(2):F395-404. PMID: 9486235.
      View in: PubMed
    Hopp's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (239) concept(s)
    _
    Co-Authors Expand Description
    See all (26) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)